Mendelian Randomisation (MR) From a naturally randomised process to a trendy research design

Main Article Content

ดร. ภก.ณัฐ นาเอก

Abstract

Mendelian Randomisation (MR) is an application of Mendel’s second law in which genotype of one trait from parents is passed on to their offspring randomly and independent on other traits (i.e., the law of independent assortment). This principle, ideally, makes MR less prone to the confounder and reverse causality, compared with a traditional observational design. In MR, single nucleotide polymorphisms (SNPs) are used as a proxy of exposure, then their association with an outcome of interest is examined. Due to the advancement of human genomic area, SNPs-chip used for the detection of SNPs becomes relatively cheap and more efficiency, and this leads to the increase in the popularity of MR study design over the last decade. In this article, the background and the key principle of MR in comparison with randomised controlled trials (RCTs) are described. Moreover, the current methodology used in MR along with the main caveats of MR design is illustrated. The aim of this article is to help health care professionals gain more confidence and basic understanding when they come across the articles about MR.

Article Details

How to Cite
1.
นาเอก ดภ. Mendelian Randomisation (MR): From a naturally randomised process to a trendy research design. crmj [internet]. 2021 Jan. 11 [cited 2025 Dec. 8];12(3):155-79. available from: https://he01.tci-thaijo.org/index.php/crmjournal/article/view/242585
Section
Special article

References

เอกสารอ้างอิง (** คือเอกสารอ้างอิงที่แนะนำให้อ่านเพิ่มเติม)
1. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39.
2. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.
3. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.
4. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.
5. Choi HY, Hafiane A, Schwertani A, Genest J. High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. Can J Cardiol. 2017 Mar;33(3):325–33.
6. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017;376(20):1933–42.
7. Chen F, Wallendszus K, Collins R, Trial C, Unit S, Kingdom U, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017;377:1217–27.
8. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet. 2012;380(9841):572–80.
9. Holmes M V., Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539–50.
10. White J, Swerdlow DI, Preiss D, Fairhurst-Hunter Z, Keating BJ, Asselbergs FW, et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol. 2016;1(6):692–9.
11. Single nucleotide polymorphism / SNP | Learn Science at Scitable [Internet]. [cited 2020 Apr 19]. Available from: https://www.nature.com/scitable/definition/snp-295/
12. Mou Z, Hyde TM, Lipska BK, Martinowich K, Wei P, Ong C-J, et al. Human Obesity Associated with an Intronic SNP in the Brain-Derived Neurotrophic Factor Locus. Cell Rep. 2015;13(6):1073–80.
13. Davies NM, Holmes M V., Davey Smith G. Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. **
14. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr. 2016;103(4):965–78. **
15. Cardiovascular Disease Knowledge Portal [Internet]. [cited 2020 May 22]. Available from: http://www.broadcvdi.org/home/portalHome
16. Bennett DA, Holmes M V. Mendelian randomisation in cardiovascular research: An introduction for clinicians. Heart. 2017;103(18):1400–7. **